ArticleAmerican journal of cancer research2017
Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Association of mucin family members with prognostic significance in pancreatic cancer patients: A meta-analysis.PloS one · 2022Pooled it
- Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis.PloS one · 2026Article
- MUC15 Ectodomain Architecture Regulates Integrin Clustering to Control Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Integrated Multiomics Validation of KeyBioMed research international · 2025Article
- MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice.Oncology · 2025Article
- New immune cell engagers for cancer immunotherapy.Nature reviews. Immunology · 2024Review
- Pancreatic Ubap2 deletion regulates glucose tolerance, inflammation, and protection from cerulein-induced pancreatitis.Cancer letters · 2023Article
- In vitro characterisation of [EJNMMI radiopharmacy and chemistry · 2023Article
- Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.Cancer letters · 2023Review
- Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.Frontiers in oncology · 2023Article
- Progress on diagnostic and prognostic markers of pancreatic cancer.Oncology research · 2023Review
- Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.Clinical and translational medicine · 2023Review
- Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.Biochimica et biophysica acta. Reviews on cancer · 2023Review
- Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.Pharmacology & therapeutics · 2022Review
- Article
- Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel, Switzerland) · 2022Review
- Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Altered glycosylation in pancreatic cancer and beyond.The Journal of experimental medicine · 2022Review
- Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Radiolabeled Antibodies for Cancer Imaging and Therapy.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is the fourth highest cause of cancer mortality in the world. It has very low survival rates owing to late diagnosis resulting from the absence of accurate diagnostic tools and effective therapies. Hence, there is a pressing need to develop new diagnostic and therapeutic tools. In the recent years, there has been new evidence implicating the importance of mucins in pancreatic carcinogenesis. Mucins belong to a group of heavily glycosylated proteins, and are often aberrantly expressed in a number of cancers such as pancreatic cancer. Therefore, this literature review will summarise the role of mucins and mucin expression in pancreatic neoplasms. Subsequently the paper will also discuss the most recent advances in the biological properties of mucins and their role in carcinogenesis and resistance to chemotherapy. Then it will conclude on the newest developments in diagnosis and therapy based on mucins for pancreatic cancer.
Indexed as
Identifiers
28670497PMC5489784W2738913456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.